Abstract
One-hundred-fifty-four patients with acute leukemia and extensive prior chemotherapy were treated with 5-Azacytidine and evaluated according to five different schedules. One-hundred-twenty patients received adequate trials; 34 patients died within 14 days of onset of treatment. Nine patients achieved a complete remission (CR) and two achieved a partial remission. Although two of the treatments have a higher remission rate, the data were not statistically significant. The median time to CR was 48 days (range 21-173). The median duration of CR was 65 days (range 39-369). There was no difference in response rate according to cell type. The median age of responders was 31 years, and 39 years for nonresponders. Proportionately there were more women among responders (5M/6F) and more men (70M/39F) among nonresponders. At onset of therapy the median leukocyte counts were similar between responding (5.4 X 10(3)) and nonresponding (5.7 X 10(3)) patients, but the proportion of leukemic cells was significantly higher among nonresponding patients (46% vs. 7%). Toxicities included nausea, vomiting, diarrhea, skin rash, myalgias, prolonged myelosuppression, hypotension, and central nervous system stupor and/or coma. Lower dose continuous infu...Continue Reading
References
Jul 1, 1976·Cancer·J A Levi, P H Wiernik
Jan 1, 1977·Advances in Pharmacology and Chemotherapy·D D von Hoff, M Slavik
Nov 1, 1978·Cancer·J H SaikiB Hoogstraten
Jan 1, 1977·Oncology·L H Einhorn, W H Bond
Jan 1, 1979·Medical and Pediatric Oncology·J HersonT Vats
Citations
Sep 12, 1998·Leukemia Research·B D Cheson
Dec 1, 1996·Blood Reviews·B H RamsahoyeK I Mills
Dec 13, 2005·Nature Clinical Practice. Oncology·Pierre Fenaux
Jun 17, 2010·Nature Reviews. Clinical Oncology·Alfonso Quintás-CardamaGuillermo Garcia-Manero
Dec 10, 2013·Hematology·Yogen Saunthararajah
Oct 20, 2010·Drug Design, Development and Therapy·Carlos E VigilGuillermo Garcia-Manero
Sep 6, 2007·Leukemia & Lymphoma·Jane E Kihslinger, Lucy A Godley
Jul 11, 2009·Expert Review of Anticancer Therapy·Vince D CataldoAlfonso Quintás-Cardama
May 22, 2010·Expert Opinion on Pharmacotherapy·Naomi Galili, Azra Raza
Mar 9, 2011·Expert Opinion on Investigational Drugs·Ernesto VignaFortunato Morabito
Jun 1, 1995·American Journal of Hematology·P P LitamH D Friedman
Oct 25, 2008·The International Journal of Biochemistry & Cell Biology·Nitin JainGuillermo Garcia-Manero
Oct 28, 2008·Cancer Treatment Reviews·Andrea Kuendgen, Ulrich Germing
Sep 3, 2010·The Prostate·Jianqing LinMichael A Carducci
Jan 1, 2014·Journal of Clinical Pharmacology·Eric LailleBarry Skikne
Apr 30, 2013·Expert Opinion on Pharmacotherapy·Janusz KrawczykFrancis J Giles
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kapil N Bhalla
Mar 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan E Dowell, John D Minna
Apr 23, 2013·Therapeutic Advances in Hematology·Cyrus KhanJames M Rossetti
Jun 13, 2008·Leukemia·G ZardoC Nervi
Oct 16, 2015·The Oncologist·Christopher R CogleGuillermo Garcia-Manero
Nov 7, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Goffin, E Eisenhauer
Oct 27, 2021·Biological Chemistry·Philipp MakowkaHubert Serve